Eosinophilic Asthma

• FDA approval · 2024-09-17
  FDA Approved: FASENRA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

  The FDA approved a supplemental application for FASENRA (benralizumab) from AstraZeneca Pharmaceuticals LP.

• FDA approval · 2019-10-03
  FDA Approved: FASENRA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

  FDA approved a supplemental application for FASENRA (benralizumab) from AstraZeneca, updating its labeling and/or indications.

• FDA approval · 2019-09-12
  FDA Approved: NUCALA — Supplemental Application (GlaxoSmithKline LLC)

  The FDA approved a supplemental application for NUCALA (mepolizumab) submitted by GlaxoSmithKline LLC.

• FDA approval · 2019-06-06
  FDA Approved: NUCALA — Original Application (GlaxoSmithKline LLC)

  FDA approves the original application for NUCALA (mepolizumab) by GlaxoSmithKline, for add-on maintenance treatment in patients with severe …

• FDA approval · 2019-01-09
  FDA Approved: CINQAIR — Supplemental Application (Teva Respiratory, LLC)

  FDA approved a supplemental application for CINQAIR (reslizumab) submitted by Teva Respiratory, LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2017-11-14
  FDA Approved: FASENRA — Original Application (AstraZeneca Pharmaceuticals LP)

  The FDA granted original approval to FASENRA (benralizumab) from AstraZeneca as a treatment for adults with severe eosinophilic asthma. This…